4月15日 - ** 药物开发商 Arbutus Biopharma ABUS.O 股价盘前上涨 4.83% 至 4.56 美元
** 该公司称，美国食品及药物管理局已授予其治疗慢性乙型肝炎（一种由乙型肝炎病毒引起的严重肝脏感染）的实验性药物imdusiran "快速通道 "资格。
** 美国食品及药物管理局的快速通道标签旨在加快未满足医疗需求的严重疾病治疗方法的开发和审查。
** 公司称，这种基于 RNA 的疗法旨在降低体内关键的乙型肝炎标志物，相信这有助于免疫系统更好地控制病毒
** 截至收盘，ABUS股价累计下跌9.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.